X-Message-Number: 13394
Date: Wed, 15 Mar 2000 15:02:40 -0800
From: Olaf Henny <>
Subject: ALT-711; New Study
References: <>


The new study report released below is a further indication that the benefits of

ALT-711 may have some rejuvenating effects on all parts of the human anatomy, 
once

clinical trials have proved the efficacy of the compound for humans. I find that
exciting and hope that they get on with it soon.

 Best,
 Olaf
  For full article see:
http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=altn&script=400

 RAMSEY, N.J., March 15 /PRNewswire/ -- Alteon Inc. (OTC Bulletin Board: ALTN),

announced today that a new pre-clinical study of ALT-711, lead Advanced 
Glycosylation

End-Product ("A.G.E.") Crosslink Breaker, has been published in the March 14th 
issue of
the Proceedings of the National Academy of Sciences (PNAS). The article details
ALT-711's ability to reverse cardiac stiffness in aged dogs, restoring the
cardiovascular system to a state found in younger animals.

 In this study, administration of ALT-711 daily for one month resulted in a 40%
reduction in age-related ventricular stiffness, or hardening. This decrease in

stiffness was accompanied by an overall improvement in cardiac function, as 
evidenced
by increased left ventricular end-diastolic volume, stroke volume and decreased
end-diastolic pressure.

Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=13394